Mohammadnezhad Ghader, Khajeamiri Yasaman, Khosravani Shirin, Pourbala Hooman, Esmaily Hadi
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC Res Notes. 2025 Jul 18;18(1):310. doi: 10.1186/s13104-025-07389-8.
Pharmacists are the key members of the multidisciplinary healthcare team for patients with multiple sclerosis (MS) and inappropriate utilization of medications and devices. This study aimed to observe the clinical value of pharmacist educational intervention (PEI) to optimize the use of interferon-βs in Iranian patients with MS through the involvement of the pharmacotherapy clinic in Shahid Kazemi specialty pharmacy in drug utilization programs.
This study received ethical approval from the Research Ethics Committee of the School of Pharmacy at Shahid Beheshti University of Medical Sciences, under approval ID IR.SBMU.PHARMACY.REC.1398.240. In this controlled pre-post survey a questionnaire consisting of 17 items assesses the patient's knowledge on the correct use of interferon-βs and the actions needed to reduce the adverse effects (AEs) of the medication and improve the control of the disease symptoms. After testing the questionnaire's validity and reliability based on the opinions of a multidisciplinary expert panel, 15 items remained. 100 patients, who were diagnosed with MS and receiving interferon-βs for at least one year, responded to the questionnaire before and after the PEI.
Patients' scores before and after receiving the educational program were 4.90 ± 5.79 and 14.44 ± 0.99, respectively. The results show that most participants do not have satisfying knowledge about their interferons, although they have injected them for more than one year, and there is a significant difference between the knowledge before and after the PEI (P < 0.001).
Our results showed that PEI could improve the pharmacotherapeutic knowledge and awareness of patients with MS about their disease-modifying therapies. Pharmacist-provided managed care is crucial in optimizing patient outcomes and the clinical burden of MS.
药剂师是多学科医疗团队的关键成员,负责为多发性硬化症(MS)患者提供药物和器械,并避免不适当的使用。本研究旨在通过参与设拉子贝赫什提医科大学沙希德·卡泽米专科药房的药物治疗诊所的药物利用项目,观察药剂师教育干预(PEI)对优化伊朗MS患者干扰素-β使用的临床价值。
本研究获得了设拉子贝赫什提医科大学药学院研究伦理委员会的伦理批准,批准号为IR.SBMU.PHARMACY.REC.1398.240。在这项对照前后调查中,一份由17项内容组成的问卷评估了患者对正确使用干扰素-β的知识,以及减少药物不良反应(AE)和改善疾病症状控制所需采取的行动。在根据多学科专家小组的意见测试问卷的有效性和可靠性后,保留了15项内容。100名被诊断为MS且接受干扰素-β治疗至少一年的患者在PEI前后对问卷进行了回答。
接受教育项目前后患者的得分分别为4.90±5.79和14.44±0.99。结果表明,尽管大多数参与者已经注射干扰素一年以上,但他们对干扰素的了解并不令人满意,PEI前后的知识水平存在显著差异(P<0.001)。
我们的结果表明,PEI可以提高MS患者对疾病改善疗法的药物治疗知识和认识。药剂师提供的管理式护理对于优化患者预后和减轻MS的临床负担至关重要。